MRSN
Mersana Therapeutics (MRSN)
$37
About Mersana Therapeutics (MRSN)
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Details
Daily high
$0.41
Daily low
$0.37
Price at open
$0.40
52 Week High
$4.71
52 Week Low
$0.37
Market cap
51.1M
Dividend yield
0.00%
Volume
2.2M
Avg. volume
3.0M
P/E ratio
-.73
Mersana Therapeutics News
Details
Daily high
$0.41
Daily low
$0.37
Price at open
$0.40
52 Week High
$4.71
52 Week Low
$0.37
Market cap
51.1M
Dividend yield
0.00%
Volume
2.2M
Avg. volume
3.0M
P/E ratio
-.73